Código QR

Gut Dysbiosis as a Potential Guide for Immunotherapy (Dis)Continuation After 2 Years in NSCLC: A Brief Report

Background: Although most phase III pivotal trials have set the duration of immune checkpoint blockers (ICB) for advanced NSCLC at 2 years, the criteria for safely discontinuing ICB remain undefined. Growing evidence links ICB efficacy to gut microbiota, positioning gut microbial taxonomic profiling...

ver descrição completa

Na minha lista:
Principais autores: Adele Bonato, MD, Claudia Parisi, MD, Priscilla Cascetta, MD, Anna Reni, MD, May-Lucie Meyer, MD, Mariona Riudavets, MD, PhD, David Planchard, MD, PhD, Benjamin Besse, MD, PhD, Jordi Remon, MD, Francesco Facchinetti, MD, PhD, Lorenzo Belluomini, MD, PhD, Lisa Derosa, MD, PhD, Fabrice Barlesi, MD, PhD
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2026-01-01
Colecção:JTO Clinical and Research Reports
Assuntos:
NSCLC
Immunotherapy
Duration
(Dis)continuation
Gut microbiome
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2666364325001468
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados